Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock Position Lifted by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. increased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 1,606.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 234,836 shares of the company's stock after acquiring an additional 221,078 shares during the period. Benjamin F. Edwards & Company Inc.'s holdings in Ginkgo Bioworks were worth $79,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DNA. Salem Investment Counselors Inc. grew its stake in shares of Ginkgo Bioworks by 110.6% during the first quarter. Salem Investment Counselors Inc. now owns 4,758,585 shares of the company's stock valued at $5,520,000 after acquiring an additional 2,499,425 shares in the last quarter. Norges Bank purchased a new stake in Ginkgo Bioworks during the 4th quarter worth approximately $24,967,000. Pinebridge Investments L.P. increased its holdings in Ginkgo Bioworks by 358.2% during the 4th quarter. Pinebridge Investments L.P. now owns 140,935 shares of the company's stock worth $238,000 after purchasing an additional 110,177 shares during the last quarter. Lingotto Investment Management LLP raised its position in shares of Ginkgo Bioworks by 34.9% in the 4th quarter. Lingotto Investment Management LLP now owns 8,511,301 shares of the company's stock valued at $14,384,000 after purchasing an additional 2,200,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Ginkgo Bioworks by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 132,780,095 shares of the company's stock valued at $224,398,000 after buying an additional 463,096 shares during the last quarter. Hedge funds and other institutional investors own 78.63% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. BTIG Research lifted their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research note on Friday, August 23rd. The Goldman Sachs Group dropped their target price on shares of Ginkgo Bioworks from $0.02 to $0.01 and set a "sell" rating for the company in a research report on Tuesday, July 9th. Finally, TD Cowen increased their price target on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $3.42.

Ginkgo Bioworks Price Performance

DNA stock traded up $0.39 during trading on Friday, hitting $8.09. 724,766 shares of the company's stock traded hands, compared to its average volume of 1,173,136. The firm has a market cap of $449.64 million, a price-to-earnings ratio of -18.39 and a beta of 1.06. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $75.20.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. The firm had revenue of $56.21 million for the quarter, compared to analyst estimates of $41.46 million. As a group, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -12.6 EPS for the current fiscal year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.